Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial)

被引：11

作者：

Gorman, Ellen A. ^{[1
]}

Rynne, Jennifer ^{[2
]}

Gardiner, Hannah J. ^{[1
]}

Rostron, Anthony J. ^{[3
,4
]}

Bannard-Smith, Jonathan ^{[5
]}

Bentley, Andrew M. ^{[6
]}

Brealey, David ^{[7
]}

Campbell, Christina ^{[8
]}

Curley, Gerard ^{[9
]}

Clarke, Mike ^{[8
]}

Dushianthan, Ahilanadan ^{[10
,11
]}

Hopkins, Phillip ^{[12
]}

Jackson, Colette ^{[8
]}

Kefela, Kallirroi ^{[13
]}

Krasnodembskaya, Anna ^{[1
]}

Laffey, John G. ^{[14
]}

McDowell, Cliona ^{[8
]}

McFarland, Margaret ^{[15
]}

McFerran, Jamie ^{[8
]}

McGuigan, Peter ^{[1
,15
]}

Perkins, Gavin D. ^{[16
,17
]}

Silversides, Jonathan ^{[1
]}

Smythe, Jon ^{[18
]}

Thompson, Jacqui ^{[19
]}

Tunnicliffe, William S. ^{[20
]}

Welters, Ingeborg D. M. ^{[21
,22
]}

Amado-Rodriguez, Laura ^{[23
,24
,25
]}

Albaiceta, Guillermo ^{[23
,24
,25
,26
]}

Williams, Barry ^{[27
]}

Shankar-Hari, Manu ^{[2
]}

McAuley, Daniel F. ^{[1
]}

O'Kane, Cecilia M. ^{[1
]}

机构：

[1] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland

[2] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland

[3] Sunderland Royal Hosp, South Tyneside & Sunderland Natl Hlth Serv Fdn Tr, Sunderland, England

[4] Newcastle Univ, Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[5] Manchester Royal Infirm, Dept Crit Care, Manchester, Lancs, England

[6] Wythenshawe Hosp, Acute Intens Care Unit, Manchester, Lancs, England

[7] Univ Coll London Hosp, London, ON, Canada

[8] Northern Ireland Clin Trials Unit, Belfast, Antrim, North Ireland

[9] Royal Coll Surgeons Ireland, Dublin, Ireland

[10] Southampton Univ Hosp, Southampton, Hants, England

[11] Univ Southampton, Natl Inst Hlth & Care Res Southampton Biomed Res, Southampton, Hants, England

[12] Kings Coll Hosp London, Kings Trauma Ctr, London, England

[13] Royal Infirm Edinburgh NHS Trust, Dept Crit Care, Edinburgh, Midlothian, Scotland

[14] Univ Galway, Regenerat Med Inst, C RAM Ctr Res Med Devices, Galway, Ireland

[15] Belfast Hlth & Social Care Trust, Dept Crit Care, Belfast, Antrim, North Ireland

[16] Univ Hosp Birmingham, Crit Care Unit, Birmingham, W Midlands, England

[17] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry, W Midlands, England

[18] Natl Hlth Serv Blood & Transplant, Birmingham, W Midlands, England

[19] Natl Hlth Serv Blood & Transplant, Birmingham, W Midlands, England

[20] Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England

[21] Royal Liverpool Univ Hosp, Intens Care Unit, Liverpool, Merseyside, England

[22] Univ Liverpool, Inst Life Course Med Sci, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England

[23] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp, Madrid, Spain

[24] Inst Invest Sanitaria Principado Asturias, Oviedo, Spain

[25] Hosp Univ Cent Asturias, Unidad Cuidados Intens Cardiol, Oviedo, Spain

[26] Univ Oviedo, Inst Univ Oncol Principado Asturias, Dept Biol Func, Oviedo, Spain

[27] Independent Patient & Publ Representat, Sherborne, England

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 208卷 / 03期

基金：

英国惠康基金;

关键词：

acute respiratory distress syndrome; coronavirus disease; mesenchymal stromal cells; clinical trial; MESENCHYMAL STEM-CELLS; ACUTE LUNG INJURY; BONE-MARROW; ADMINISTRATION REALIST; MITOCHONDRIAL TRANSFER; MACROPHAGES; MANAGEMENT; MODELS; BLIND; ARDS;

D O I：

10.1164/rccm.202302-0297OC

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Rationale: Mesenchymal stromal cells (MSCs) may modulate inflammation, promoting repair in coronavirus disease (COVID-19)-related acute respiratory distress syndrome (ARDS). Objectives: We investigated the safety and efficacy of ORBCEL-C (CD362 [cluster of differentiation 362]-enriched, umbilical cord-derived MSCs) in COVID-19-related ARDS. Methods: In this multicenter, randomized, double-blind, allocation-concealed, placebo-controlled trial (NCT 03042143), patients with moderate to severe COVID-19-related ARDS were randomized to receive ORBCEL-C (400 million cells) or placebo (Plasma-Lyte 148). The primary safety and efficacy outcomes were the incidence of serious adverse events and oxygenation index at Day 7, respectively. Secondary outcomes included respiratory compliance, driving pressure, PaO2:FIO2 ratio, and Sequential Organ Failure Assessment score. Clinical outcomes relating to duration of ventilation, lengths of ICU and hospital stays, and mortality were collected. Long-term follow-up included diagnosis of interstitial lung disease at 1 year and significant medical events and mortality at 2 years. Transcriptomic analysis was performed on whole blood at Days 0, 4, and 7. Measurements and Main Results: Sixty participants were recruited (final analysis: n = 30 received ORBCEL-C, n= 29 received placebo; 1 participant in the placebo group withdrew consent). Six serious adverse events occurred in the ORBCEL-C group and three in the placebo group (risk ratio, 2.9 [95% confidence interval, 0.6-13.2]; P = 0.25). Day 7 mean (SD) oxygenation index did not differ (ORBCEL-C, 98.3 [57.2] cm H2O/kPa; placebo, 96.6 [67.3] cm H2O/kPa). There were no differences in secondary surrogate outcomes or in mortality at Day 28, Day 90, 1 year, or 2 years. There was no difference in the prevalence of interstitial lung disease at 1 year or significant medical events up to 2 years. ORBCEL-C modulated the peripheral blood transcriptome. Conclusion: ORBCEL-C MSCs were safe in subjects with moderate to severe COVID-19-related ARDS but did not improve surrogates of pulmonary organ dysfunction.

引用

页码：256 / 269

页数：14

共 50 条

[1] Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cell Administration (REALIST-COVID) Phase 2 Randomised Controlled Trial
Gorman, E.
McAuley, D. F.
Rostron, A. J.
Shankar-Hari, M.
Bannard-Smith, J.
Bentley, A. M.
Brealey, D.
Campbell, C.
Curley, G.
Clarke, M.
Dushianthan, A.
Hopkins, P.
Jackson, C.
Kefala, K.
Krasnodembskaya, A.
Laffey, J. G.
McDowell, C.
McFarland, M.
McFerran, J.
McGuigan, P.
Perkins, G. D.
Silversides, J.
Smythe, J.
Thompson, J.
Tunnicliffe, W. S.
Welters, I. D. M.
Williams, B.
O'Kane, C. M.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[2] REPAIR OF ACUTE RESPIRATORY DISTRESS SYNDROME IN COVID-19 BY STROMAL CELLS (REALIST-COVID TRIAL): 1 YEAR FOLLOW UP FOR SAFETY AND PULMONARY DYSFUNCTION
Gardiner, H. J.
Gorman, E. A.
Rostron, A. J.
Shankar-Hari, M.
Bannard-Smith, J.
Bentley, A. M.
Brealey, D.
Campbell, C.
Curley, G.
Clarke, M.
Dushianthan, A.
Hopkins, P.
Jackson, C.
Kefela, K.
Laffey, J. G.
McDowell, C.
McFarland, M.
McFerran, J.
McGuigan, P.
Perkins, G. D.
Silversides, J.
Smythe, J.
Thompson, J.
Tunnicliffe, W. S.
Welters, I. D. M.
Williams, B.
McAuley, D. F.
O'Kane, C. M.
[J]. THORAX, 2022, 77 : A30 - A30
[3] COVID-19: Mesenchymal stromal cells in acute respiratory distress syndrome?
Simon, Annika
[J]. PNEUMOLOGIE, 2023, 77 (09):
[4] Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial
Gorman, Ellen
Shankar-Hari, Manu
Hopkins, Phil
Tunnicliffe, William S.
Perkins, Gavin D.
Silversides, Jonathan
McGuigan, Peter
Jackson, Colette
Boyle, Roisin
McFerran, Jamie
McDowell, Cliona
Campbell, Christina
McFarland, Margaret
Smythe, Jon
Thompson, Jacqui
Williams, Barry
Curley, Gerard
Laffey, John G.
Clarke, Mike
O'Kane, Cecilia
McAuley, Daniel F.
[J]. TRIALS, 2020, 21 (01)
[5] Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial
Ellen Gorman
Manu Shankar-Hari
Phil Hopkins
William S. Tunnicliffe
Gavin D. Perkins
Jonathan Silversides
Peter McGuigan
Colette Jackson
Roisin Boyle
Jamie McFerran
Cliona McDowell
Christina Campbell
Margaret McFarland
Jon Smythe
Jacqui Thompson
Barry Williams
Gerard Curley
John G. Laffey
Mike Clarke
Cecilia O’Kane
Daniel F. McAuley
[J]. Trials, 21
[6] A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19
Bowdish, Michael E.
Barkauskas, Christina E.
Overbey, Jessica R.
Gottlieb, Robert L.
Osman, Keren
Duggal, Abhijit
Marks, Mary E.
Hupf, Jonathan
Fernandes, Eustace
Leshnower, Bradley G.
Golob, Jonathan L.
Iribarne, Alexander
Rassias, Athos J.
Moquete, Ellen G.
O'Sullivan, Karen
Chang, Helena L.
Williams, Judson B.
Parnia, Sam
Patel, Nirav C.
Desai, Nimesh D.
Vekstein, Andrew M.
Hollister, Beth A.
Possemato, Tammie
Romero, Christian
Hou, Peter C.
Burke, Elizabeth
Hayes, Jack
Grossman, Fred
Itescu, Silviu
Gillinov, Marc
Pagani, Francis D.
O'Gara, Patrick T.
Mack, Michael J.
Smith, Peter K.
Bagiella, Emilia
Moskowitz, Alan J.
Gelijns, Annetine C.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (03) : 261 - 270
[7] Acute respiratory distress syndrome in COVID-19
Dadashzadeh, Nahid
Farshid, Saman
Valizadeh, Rohollah
Nanbakhsh, Mohammad
Rahimi, Mohsen Mohammad
[J]. IMMUNOPATHOLOGIA PERSA, 2020, 6 (02):
[8] Understanding the Role of Mesenchymal Stromal Cells in Treating COVID-19 Acute Respiratory Distress Syndrome
O'Kane, Cecilia M.
Matthay, Michael A.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (03) : 231 - 233
[9] Understanding COVID-19 Acute Respiratory Distress Syndrome
Singh, Anchit Raj
Kumar, Raj
Sinha, Anwita
[J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2022, 19 (01) : 150 - 150
[10] MESENCHYMAL STROMAL CELL THERAPY FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19
Brown, Stacey-Ann Whittaker
Iancu-Rubin, Camelia
Aboelela, Adam
Abrahams, Alex
Burke, Elizabeth
Drummond, Tiffany
Grossman, Fred
Itescu, Silviu
Lagdameo, Jonathan
Lin, Jung-Yi
Mark, Alexis
Levine, John
Osman, Keren
[J]. CRITICAL CARE MEDICINE, 2021, 49 (01) : 77 - 77

← 1 2 3 4 5 →